A 10-year-old female student presented with nephrotic syndrome. She responded well to oral prednisone treatment but after 2 years of remission, presented with edema and increased proteinuria. Her renal function was normal. An elevated urinary albumin:protein ratio would be suggestive of relapse of her nephrotic syndrome. The document then discusses definitions, pathogenesis, management and treatment guidelines for minimal change disease in children.
This document provides information on the clinical and pathological approach to jaundice. It defines jaundice as a yellowish discoloration of the skin and mucous membranes due to increased bilirubin levels in the blood. Jaundice is categorized as pre-hepatic, hepatic, or post-hepatic. Pre-hepatic causes include various hemolytic anemias. Hepatic causes include physiologic jaundice of newborns and hepatitis. Post-hepatic causes involve issues with the bile ducts. The document outlines clues for diagnosing different types of jaundice and discusses evaluation and management of neonatal jaundice.
Kawasaki disease is an autoimmune disease that causes inflammation in blood vessels throughout the body. It was first described in 1967 by Dr. Kawasaki in Japan. It most commonly affects children under 5 years old. Without treatment, it can lead to fatal coronary artery aneurysms in some children. The cause is unknown but likely involves genetic and environmental factors such as a viral or bacterial infection. Diagnosis is based on symptoms that include prolonged fever and changes in lips, mouth, hands and feet. Echocardiograms are used to check for heart complications which include aneurysms and heart valve issues.
Minimal change disease (MCD) is a histologic pattern seen on kidney biopsy that is characterized by nephrotic syndrome without immune deposits or inflammation. It is most common in children but can occur in adults. The pathogenesis involves circulating permeability factors that cause foot process effacement and proteinuria. MCD is highly responsive to steroids, with remission occurring in 80-85% of adults, though relapses are common. Treatment involves corticosteroids, with slower tapers needed in adults to minimize relapses. Refractory cases may require additional immunosuppression. The prognosis is generally excellent if the disease is steroid-responsive.
Minimal Change Disease (MCD), also known as Minimal Change Nephropathy, is a kidney disorder characterized by diffuse effacement and loss of foot processes in the glomeruli seen on electron microscopy. It is the most common cause of nephrotic syndrome in children aged 1-7 years and accounts for about 90% of cases. Boys are more commonly affected than girls. MCD is thought to be caused by an abnormal immune response involving T-cells and cytokines that damages the glomerular filtration barrier. This results in proteinuria but no significant pathology on light microscopy. The clinical features include nephrotic syndrome. The prognosis is generally good as over 90% will respond to corticosteroid therapy
A 19-year-old male presented with fever, abdominal lump, fullness, loss of appetite, and weakness for 3-4 years. Physical examination revealed anemia, fever, pale skin, and massive splenomegaly and mild hepatomegaly. Tests showed pancytopenia and previous positive malaria tests. The diagnosis was Tropical Splenomegaly Syndrome due to repeated malarial infections over many years. Management involves long-term antimalarial medication to reduce IgM levels and spleen/liver size. The prognosis is generally good if managed properly but increased risk of infections and complications.
Meckel's diverticulum is the most common congenital abnormality of the gastrointestinal tract, occurring in approximately 2% of the population. It results from incomplete obliteration of the vitelline duct during fetal development. While most cases are asymptomatic, Meckel's diverticulum can cause complications like bleeding, diverticulitis, intestinal obstruction, and intussusception due to heterotopic gastric or pancreatic tissue. Diagnosis is often made through scans like a technetium-99m pertechnetate scan or CT scan. Treatment involves surgical resection of the diverticulum and adjacent bowel segment for symptomatic cases.
A 3-year-old boy presented with puffy eyes and edema. Examination found pitting edema, elevated heart rate, and proteinuria. Tests showed normal kidney and liver function. He was diagnosed with nephrotic syndrome based on his symptoms and urine protein level. Nephrotic syndrome is characterized by protein in the urine and symptoms of edema, low albumin, and high cholesterol or lipids. The majority of cases in children are idiopathic and due to minimal change disease. Treatment involves supportive care, steroids, and other medications depending on response and side effects.
This document provides information on the clinical and pathological approach to jaundice. It defines jaundice as a yellowish discoloration of the skin and mucous membranes due to increased bilirubin levels in the blood. Jaundice is categorized as pre-hepatic, hepatic, or post-hepatic. Pre-hepatic causes include various hemolytic anemias. Hepatic causes include physiologic jaundice of newborns and hepatitis. Post-hepatic causes involve issues with the bile ducts. The document outlines clues for diagnosing different types of jaundice and discusses evaluation and management of neonatal jaundice.
Kawasaki disease is an autoimmune disease that causes inflammation in blood vessels throughout the body. It was first described in 1967 by Dr. Kawasaki in Japan. It most commonly affects children under 5 years old. Without treatment, it can lead to fatal coronary artery aneurysms in some children. The cause is unknown but likely involves genetic and environmental factors such as a viral or bacterial infection. Diagnosis is based on symptoms that include prolonged fever and changes in lips, mouth, hands and feet. Echocardiograms are used to check for heart complications which include aneurysms and heart valve issues.
Minimal change disease (MCD) is a histologic pattern seen on kidney biopsy that is characterized by nephrotic syndrome without immune deposits or inflammation. It is most common in children but can occur in adults. The pathogenesis involves circulating permeability factors that cause foot process effacement and proteinuria. MCD is highly responsive to steroids, with remission occurring in 80-85% of adults, though relapses are common. Treatment involves corticosteroids, with slower tapers needed in adults to minimize relapses. Refractory cases may require additional immunosuppression. The prognosis is generally excellent if the disease is steroid-responsive.
Minimal Change Disease (MCD), also known as Minimal Change Nephropathy, is a kidney disorder characterized by diffuse effacement and loss of foot processes in the glomeruli seen on electron microscopy. It is the most common cause of nephrotic syndrome in children aged 1-7 years and accounts for about 90% of cases. Boys are more commonly affected than girls. MCD is thought to be caused by an abnormal immune response involving T-cells and cytokines that damages the glomerular filtration barrier. This results in proteinuria but no significant pathology on light microscopy. The clinical features include nephrotic syndrome. The prognosis is generally good as over 90% will respond to corticosteroid therapy
A 19-year-old male presented with fever, abdominal lump, fullness, loss of appetite, and weakness for 3-4 years. Physical examination revealed anemia, fever, pale skin, and massive splenomegaly and mild hepatomegaly. Tests showed pancytopenia and previous positive malaria tests. The diagnosis was Tropical Splenomegaly Syndrome due to repeated malarial infections over many years. Management involves long-term antimalarial medication to reduce IgM levels and spleen/liver size. The prognosis is generally good if managed properly but increased risk of infections and complications.
Meckel's diverticulum is the most common congenital abnormality of the gastrointestinal tract, occurring in approximately 2% of the population. It results from incomplete obliteration of the vitelline duct during fetal development. While most cases are asymptomatic, Meckel's diverticulum can cause complications like bleeding, diverticulitis, intestinal obstruction, and intussusception due to heterotopic gastric or pancreatic tissue. Diagnosis is often made through scans like a technetium-99m pertechnetate scan or CT scan. Treatment involves surgical resection of the diverticulum and adjacent bowel segment for symptomatic cases.
A 3-year-old boy presented with puffy eyes and edema. Examination found pitting edema, elevated heart rate, and proteinuria. Tests showed normal kidney and liver function. He was diagnosed with nephrotic syndrome based on his symptoms and urine protein level. Nephrotic syndrome is characterized by protein in the urine and symptoms of edema, low albumin, and high cholesterol or lipids. The majority of cases in children are idiopathic and due to minimal change disease. Treatment involves supportive care, steroids, and other medications depending on response and side effects.
Nephrotic syndrome affects 1-3 per 100,000 children below age 16. It is most commonly caused by minimal change disease in children, responding to corticosteroid therapy in 80% of cases. A kidney biopsy is generally not required initially as most children will respond to corticosteroids. For steroid-sensitive nephrotic syndrome, treatment involves prednisone for 12 weeks including 4-6 weeks daily followed by alternate-day dosing for 2-5 months. Frequently relapsing or steroid-dependent cases may be treated with corticosteroid-sparing agents such as cyclophosphamide, levamisole, or calcineurin inhibitors.
This document discusses lupus nephritis, including its pathophysiology, risk factors, clinical presentation, investigations, classification, treatment, and prognosis. Key points include:
- Lupus nephritis is a serious manifestation of systemic lupus erythematosus caused by autoantibodies forming immune complexes that deposit in the glomeruli.
- It is classified based on renal biopsy findings, with classes III and IV having the highest risk of progressing to end-stage renal disease.
- Treatment involves immunosuppressive induction therapy with corticosteroids and cyclophosphamide or mycophenolate mofetil to rapidly decrease inflammation, followed by long-term maintenance
Pancreatitis is an inflammatory condition of the pancreas. Two major forms : acute pancreatitis (is reversible) and chronic pancreatitis(is irreversible).
This document provides information on rapidly progressive glomerulonephritis (RPGN), including definitions, classifications, pathogenesis, clinical features, pathology, treatment, and epidemiology of the main types. It discusses anti-glomerular basement membrane glomerulonephritis, immune complex-mediated RPGN, and pauci-immune RPGN. The pathology and clinical presentation of each type is described. Treatment typically involves immunosuppression with corticosteroids and cyclophosphamide along with plasmapheresis in severe cases.
This document provides an overview of Hirschsprung's disease, including its epidemiology, embryology, pathology, clinical presentation, diagnosis, treatment, and complications. Hirschsprung's disease is a congenital disorder caused by the absence of ganglion cells in parts of the colon, resulting in bowel obstruction. It occurs in approximately 1 in 1500-7000 newborns and is diagnosed based on symptoms of constipation as well as diagnostic tests like rectal biopsy and barium enema. The standard surgical treatments are Swenson's, Duhamel's, and Soave's procedures to remove the aganglionic segment and reconnect the bowel. Complications can include infection, stricture, and enterocolitis
Wilson disease is an autosomal recessive genetic disorder caused by mutations in the ATP7B gene, which encodes a copper-transporting ATPase. This leads to toxic buildup of copper in the liver, brain, and eyes. Accumulated copper causes tissue damage through free radical formation, binding to cellular proteins, and displacing other metals in enzymes. In children, copper escapes the damaged liver and deposits in other tissues like the brain, kidneys, and cornea. Clinical features include liver disease, neurological or psychiatric symptoms, hypoarathyroidism, and a brown ring around the eye. Diagnosis involves testing for increased urinary copper, decreased serum ceruloplasmin, and high copper levels in liver biopsy
The document discusses several congenital and acquired abnormalities of the small and large intestines. It describes Meckel's diverticulum, Hirschsprung's disease, infectious enterocolitis including rotavirus, and necrotizing enterocolitis in neonates. It also discusses malabsorption syndromes such as celiac disease, tropical sprue, and Whipple's disease. Inflammatory bowel diseases like Crohn's disease and ulcerative colitis are compared. Other topics covered include intestinal obstruction, intestinal ischemia, hemorrhoids, diverticular disease, and intestinal neoplasms.
The document discusses malnutrition as a major cause of child deaths globally and in India. It outlines the signs and symptoms of severe acute malnutrition (SAM) in children and the 10 step treatment protocol to first stabilize and then rehabilitate malnourished children. This involves restoring blood glucose and body temperature, oral rehydration for diarrhea, vitamin and mineral supplements, and gradually advancing children to higher calorie therapeutic feeds. The goal is to discharge children once they have gained adequate weight and are free from infection. Prevention strategies are needed at the national, community and family level.
This document provides an overview of acute glomerulonephritis (AGN) and several related kidney conditions. It discusses the pathogenesis, pathology, clinical manifestations, diagnosis, treatment, and prognosis of AGN and other glomerular diseases including post-streptococcal glomerulonephritis, membranous glomerulonephritis, membranoproliferative glomerulonephritis, lupus nephritis, Henoch-Schonlein purpura nephritis, and rapidly progressive glomerulonephritis. Key pathological features, diagnostic tests, and treatment approaches are described for each condition.
This document discusses the approach to nephrotic syndrome. It describes the case of a 15-year old male patient presenting with swelling of the face and limbs and decreased urine output. Examinations and investigations revealed nephrotic syndrome. A renal biopsy showed membranoproliferative glomerulonephritis. The document then discusses nephrotic syndrome including definitions, classifications of primary and secondary causes, diagnostic workup including renal biopsy, complications of renal biopsy, and treatment approach.
Nephrotic syndrome is characterized by heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. It is classified based on etiology and histology. The majority have minimal change disease which is steroid sensitive. Treatment involves corticosteroids for initial and relapse episodes. For frequent relapses or steroid dependence, immunosuppressants like levamisole or cyclophosphamide are used. Steroid resistant disease requires calcineurin inhibitors or mycophenolate mofetil. Supportive care focuses on diet, edema management, and patient education. Complications include infections, thrombosis, and steroid side effects which require monitoring and prevention.
Acute glomerulonephritis is an acute inflammation of the renal glomeruli characterized by sudden onset of oliguria, hematuria, hypertension and edema. It is commonly caused by a streptococcal infection and results in the deposition of immune complexes in the glomeruli. On pathology, glomeruli appear enlarged and infiltrated by polymorphs with epithelial crescents. Immunofluorescence shows "lumpy-bumpy" deposits of immunoglobulin and complement. Management involves controlling hypertension and edema with diuretics, treating any underlying infection, and managing complications such as acute renal failure. The prognosis is generally good with complete recovery in most cases.
MECKEL’S DIVERTICULUM- Pediatric Surgery
Dear Viewers,
Greetings from “Surgical Educator”
Today I have uploaded a video on Meckel’s diverticulum. This is a great imitator because of its varied ways of presentation. It can present as bleeding per rectum, intestinal obstruction, pain abdomen and fecal umbilical discharge. I have discussed the epidemiology, etiology, embryology, clinical features, investigations, differential diagnosis and treatment of Meckel’s diverticulum in this video. Hope you will enjoy the video. You can watch the video in the following links:
surgicaleducator.blogspot.com
youtube.com/c/surgicaleducator
Thank you for watching the video.
Let's learn the pharmacology related to nephrotic syndrome - features of nephrotic syndrome with underlying mechanisms, objectives of treatment, and management of the nephrotic syndrome.
Salmonella enterica serovar Typhi causes enteric fever or typhoid fever in children. It is transmitted through ingestion of contaminated food or water. In the body, it invades the intestinal mucosa and spreads to the bloodstream and reticuloendothelial system. Clinical features include sustained high fever, abdominal discomfort, diarrhea, and complications affecting the nervous, cardiovascular or pulmonary systems. Diagnosis involves blood or stool cultures. Treatment recommended is with third generation cephalosporins like cefixime or ceftriaxone. Vaccines provide protection, especially the Vi conjugate vaccine for younger children.
Neonatal anaemia: overview of pathophysiology, clinical approaches and compre...Gabriel Shamavu
This document provides an outline and introduction to the topics of neonatal anemia. It discusses physiological anemia of newborns, anemia of prematurity, and pathologic anemia. For physiological anemia, it explains the normal developmental process of erythropoiesis and hemoglobin production during fetal development and after birth. It also describes the typical decline in hemoglobin levels seen in both term and preterm infants in the first few weeks of life. For anemia of prematurity, it notes this is an exaggerated form of physiological anemia seen in very preterm infants less than 32 weeks gestation. The document lays the foundation for further discussion of these topics in neonatal anemia.
This document provides an overview of acute gastrointestinal bleeding. It defines upper gastrointestinal bleeding and discusses its causes, including variceal and non-variceal sources. Signs and symptoms are outlined. The approach involves taking a thorough history and physical exam. Key lab tests include CBC, LFTs, coagulation panels and endoscopy. Treatment depends on the bleeding source, and may include endoscopic methods, radiological embolization, surgery, or medications like PPIs and vasoactive drugs. Complications are also reviewed.
NEPHRITIC SYNDROME / APSGN IN CHILDREN Sajjad Sabir
This document provides information about Acute Poststreptococcal Glomerulonephritis (APSGN). It begins by describing the features of acute nephritic syndrome which is characterized by gross hematuria, edema, hypertension, and renal insufficiency. It then discusses the pathology, clinical manifestations, diagnosis, and management of APSGN. APSGN is caused by a previous streptococcal infection and results in immune complex deposition in the glomeruli. It presents abruptly with hematuria, edema, hypertension, and sometimes renal insufficiency. Treatment focuses on supporting kidney function and controlling blood pressure while the patient recovers over 6-8 weeks. Prognosis is generally good with complete recovery in over 95
This document provides an overview of minimal change nephrotic syndrome (MCD), including its pathogenesis, epidemiology, clinical manifestations, pathology, variants, differential diagnosis, natural history, and treatment. MCD is the most common cause of nephrotic syndrome in children and accounts for 10-15% of cases in adults. It is defined by normal glomeruli on light microscopy but fusion of epithelial foot processes on electron microscopy. Treatment involves corticosteroids, which achieve remission in over 80% of adults. For frequent relapsing or steroid dependent patients, cyclophosphamide, calcineurin inhibitors, or mycophenolate mofetil may be used.
This document discusses nephrotic syndrome and its treatment protocols. It defines nephrotic syndrome as having heavy proteinuria, hypoalbuminemia, hyperlipidemia, and edema. It describes steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS), and their treatment options including corticosteroids, calcineurin inhibitors, cyclophosphamide, mycophenolate mofetil, and rituximab. The prognosis is generally good for SSNS but poorer for SRNS, as treatment options are more limited due to resistance to standard immunosuppressive agents.
Nephrotic syndrome affects 1-3 per 100,000 children below age 16. It is most commonly caused by minimal change disease in children, responding to corticosteroid therapy in 80% of cases. A kidney biopsy is generally not required initially as most children will respond to corticosteroids. For steroid-sensitive nephrotic syndrome, treatment involves prednisone for 12 weeks including 4-6 weeks daily followed by alternate-day dosing for 2-5 months. Frequently relapsing or steroid-dependent cases may be treated with corticosteroid-sparing agents such as cyclophosphamide, levamisole, or calcineurin inhibitors.
This document discusses lupus nephritis, including its pathophysiology, risk factors, clinical presentation, investigations, classification, treatment, and prognosis. Key points include:
- Lupus nephritis is a serious manifestation of systemic lupus erythematosus caused by autoantibodies forming immune complexes that deposit in the glomeruli.
- It is classified based on renal biopsy findings, with classes III and IV having the highest risk of progressing to end-stage renal disease.
- Treatment involves immunosuppressive induction therapy with corticosteroids and cyclophosphamide or mycophenolate mofetil to rapidly decrease inflammation, followed by long-term maintenance
Pancreatitis is an inflammatory condition of the pancreas. Two major forms : acute pancreatitis (is reversible) and chronic pancreatitis(is irreversible).
This document provides information on rapidly progressive glomerulonephritis (RPGN), including definitions, classifications, pathogenesis, clinical features, pathology, treatment, and epidemiology of the main types. It discusses anti-glomerular basement membrane glomerulonephritis, immune complex-mediated RPGN, and pauci-immune RPGN. The pathology and clinical presentation of each type is described. Treatment typically involves immunosuppression with corticosteroids and cyclophosphamide along with plasmapheresis in severe cases.
This document provides an overview of Hirschsprung's disease, including its epidemiology, embryology, pathology, clinical presentation, diagnosis, treatment, and complications. Hirschsprung's disease is a congenital disorder caused by the absence of ganglion cells in parts of the colon, resulting in bowel obstruction. It occurs in approximately 1 in 1500-7000 newborns and is diagnosed based on symptoms of constipation as well as diagnostic tests like rectal biopsy and barium enema. The standard surgical treatments are Swenson's, Duhamel's, and Soave's procedures to remove the aganglionic segment and reconnect the bowel. Complications can include infection, stricture, and enterocolitis
Wilson disease is an autosomal recessive genetic disorder caused by mutations in the ATP7B gene, which encodes a copper-transporting ATPase. This leads to toxic buildup of copper in the liver, brain, and eyes. Accumulated copper causes tissue damage through free radical formation, binding to cellular proteins, and displacing other metals in enzymes. In children, copper escapes the damaged liver and deposits in other tissues like the brain, kidneys, and cornea. Clinical features include liver disease, neurological or psychiatric symptoms, hypoarathyroidism, and a brown ring around the eye. Diagnosis involves testing for increased urinary copper, decreased serum ceruloplasmin, and high copper levels in liver biopsy
The document discusses several congenital and acquired abnormalities of the small and large intestines. It describes Meckel's diverticulum, Hirschsprung's disease, infectious enterocolitis including rotavirus, and necrotizing enterocolitis in neonates. It also discusses malabsorption syndromes such as celiac disease, tropical sprue, and Whipple's disease. Inflammatory bowel diseases like Crohn's disease and ulcerative colitis are compared. Other topics covered include intestinal obstruction, intestinal ischemia, hemorrhoids, diverticular disease, and intestinal neoplasms.
The document discusses malnutrition as a major cause of child deaths globally and in India. It outlines the signs and symptoms of severe acute malnutrition (SAM) in children and the 10 step treatment protocol to first stabilize and then rehabilitate malnourished children. This involves restoring blood glucose and body temperature, oral rehydration for diarrhea, vitamin and mineral supplements, and gradually advancing children to higher calorie therapeutic feeds. The goal is to discharge children once they have gained adequate weight and are free from infection. Prevention strategies are needed at the national, community and family level.
This document provides an overview of acute glomerulonephritis (AGN) and several related kidney conditions. It discusses the pathogenesis, pathology, clinical manifestations, diagnosis, treatment, and prognosis of AGN and other glomerular diseases including post-streptococcal glomerulonephritis, membranous glomerulonephritis, membranoproliferative glomerulonephritis, lupus nephritis, Henoch-Schonlein purpura nephritis, and rapidly progressive glomerulonephritis. Key pathological features, diagnostic tests, and treatment approaches are described for each condition.
This document discusses the approach to nephrotic syndrome. It describes the case of a 15-year old male patient presenting with swelling of the face and limbs and decreased urine output. Examinations and investigations revealed nephrotic syndrome. A renal biopsy showed membranoproliferative glomerulonephritis. The document then discusses nephrotic syndrome including definitions, classifications of primary and secondary causes, diagnostic workup including renal biopsy, complications of renal biopsy, and treatment approach.
Nephrotic syndrome is characterized by heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. It is classified based on etiology and histology. The majority have minimal change disease which is steroid sensitive. Treatment involves corticosteroids for initial and relapse episodes. For frequent relapses or steroid dependence, immunosuppressants like levamisole or cyclophosphamide are used. Steroid resistant disease requires calcineurin inhibitors or mycophenolate mofetil. Supportive care focuses on diet, edema management, and patient education. Complications include infections, thrombosis, and steroid side effects which require monitoring and prevention.
Acute glomerulonephritis is an acute inflammation of the renal glomeruli characterized by sudden onset of oliguria, hematuria, hypertension and edema. It is commonly caused by a streptococcal infection and results in the deposition of immune complexes in the glomeruli. On pathology, glomeruli appear enlarged and infiltrated by polymorphs with epithelial crescents. Immunofluorescence shows "lumpy-bumpy" deposits of immunoglobulin and complement. Management involves controlling hypertension and edema with diuretics, treating any underlying infection, and managing complications such as acute renal failure. The prognosis is generally good with complete recovery in most cases.
MECKEL’S DIVERTICULUM- Pediatric Surgery
Dear Viewers,
Greetings from “Surgical Educator”
Today I have uploaded a video on Meckel’s diverticulum. This is a great imitator because of its varied ways of presentation. It can present as bleeding per rectum, intestinal obstruction, pain abdomen and fecal umbilical discharge. I have discussed the epidemiology, etiology, embryology, clinical features, investigations, differential diagnosis and treatment of Meckel’s diverticulum in this video. Hope you will enjoy the video. You can watch the video in the following links:
surgicaleducator.blogspot.com
youtube.com/c/surgicaleducator
Thank you for watching the video.
Let's learn the pharmacology related to nephrotic syndrome - features of nephrotic syndrome with underlying mechanisms, objectives of treatment, and management of the nephrotic syndrome.
Salmonella enterica serovar Typhi causes enteric fever or typhoid fever in children. It is transmitted through ingestion of contaminated food or water. In the body, it invades the intestinal mucosa and spreads to the bloodstream and reticuloendothelial system. Clinical features include sustained high fever, abdominal discomfort, diarrhea, and complications affecting the nervous, cardiovascular or pulmonary systems. Diagnosis involves blood or stool cultures. Treatment recommended is with third generation cephalosporins like cefixime or ceftriaxone. Vaccines provide protection, especially the Vi conjugate vaccine for younger children.
Neonatal anaemia: overview of pathophysiology, clinical approaches and compre...Gabriel Shamavu
This document provides an outline and introduction to the topics of neonatal anemia. It discusses physiological anemia of newborns, anemia of prematurity, and pathologic anemia. For physiological anemia, it explains the normal developmental process of erythropoiesis and hemoglobin production during fetal development and after birth. It also describes the typical decline in hemoglobin levels seen in both term and preterm infants in the first few weeks of life. For anemia of prematurity, it notes this is an exaggerated form of physiological anemia seen in very preterm infants less than 32 weeks gestation. The document lays the foundation for further discussion of these topics in neonatal anemia.
This document provides an overview of acute gastrointestinal bleeding. It defines upper gastrointestinal bleeding and discusses its causes, including variceal and non-variceal sources. Signs and symptoms are outlined. The approach involves taking a thorough history and physical exam. Key lab tests include CBC, LFTs, coagulation panels and endoscopy. Treatment depends on the bleeding source, and may include endoscopic methods, radiological embolization, surgery, or medications like PPIs and vasoactive drugs. Complications are also reviewed.
NEPHRITIC SYNDROME / APSGN IN CHILDREN Sajjad Sabir
This document provides information about Acute Poststreptococcal Glomerulonephritis (APSGN). It begins by describing the features of acute nephritic syndrome which is characterized by gross hematuria, edema, hypertension, and renal insufficiency. It then discusses the pathology, clinical manifestations, diagnosis, and management of APSGN. APSGN is caused by a previous streptococcal infection and results in immune complex deposition in the glomeruli. It presents abruptly with hematuria, edema, hypertension, and sometimes renal insufficiency. Treatment focuses on supporting kidney function and controlling blood pressure while the patient recovers over 6-8 weeks. Prognosis is generally good with complete recovery in over 95
This document provides an overview of minimal change nephrotic syndrome (MCD), including its pathogenesis, epidemiology, clinical manifestations, pathology, variants, differential diagnosis, natural history, and treatment. MCD is the most common cause of nephrotic syndrome in children and accounts for 10-15% of cases in adults. It is defined by normal glomeruli on light microscopy but fusion of epithelial foot processes on electron microscopy. Treatment involves corticosteroids, which achieve remission in over 80% of adults. For frequent relapsing or steroid dependent patients, cyclophosphamide, calcineurin inhibitors, or mycophenolate mofetil may be used.
This document discusses nephrotic syndrome and its treatment protocols. It defines nephrotic syndrome as having heavy proteinuria, hypoalbuminemia, hyperlipidemia, and edema. It describes steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS), and their treatment options including corticosteroids, calcineurin inhibitors, cyclophosphamide, mycophenolate mofetil, and rituximab. The prognosis is generally good for SSNS but poorer for SRNS, as treatment options are more limited due to resistance to standard immunosuppressive agents.
This document provides information about nephrotic syndrome including its definition, causes, signs and symptoms, investigations, management, and complications. Nephrotic syndrome is characterized by proteinuria, hypoalbuminemia, edema, and hyperlipidemia. It can be caused by primary/idiopathic conditions like minimal change disease or secondary causes such as SLE, diabetes, or drugs. Management involves dietary modifications, diuretics, steroid therapy, and immunosuppressive drugs depending on disease severity and response to treatment. Complications include thrombosis, peritonitis, and hypovolemia which require prompt intervention.
This document provides an overview of the approach to pediatric nephrotic syndrome. It discusses the epidemiology, clinical evaluation, diagnostic criteria and management of nephrotic syndrome. The majority of cases are steroid-sensitive minimal change disease that respond well to steroid therapy. For cases that are steroid-resistant, further evaluation with renal biopsy and genetic testing is recommended to help guide treatment, which may include calcineurin inhibitors, rituximab or supportive care depending on the specific cause and progression. The goal of treatment is achieving remission while minimizing medication side effects and delaying end stage renal disease.
Nephrotic syndrome is characterized by nephrotic range proteinuria, hypoalbuminemia, hyperlipidemia, and edema. It can be primary, caused by diseases limited to the kidney, or secondary, caused by diseases involving other organ systems. Primary causes include minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy. Management involves treating any underlying causes, controlling edema and hyperlipidemia, and using corticosteroids or other immunosuppressive drugs to induce remission in frequent relapsers or steroid-dependent patients.
Nephrotic syndrome is a common pediatric renal condition characterized by proteinuria, hypoalbuminemia, edema, and hypercholesterolemia. The most common causes are minimal change disease and focal segmental glomerulosclerosis. Treatment involves steroid therapy, but many children are steroid resistant or dependent, requiring additional therapies like calcineurin inhibitors or cytotoxic drugs. Renal biopsy helps determine prognosis and guides management, as focal segmental glomerulosclerosis carries a higher risk of steroid resistance. Timely diagnosis and treatment are important to prevent complications like infection.
nephrotic syndrome final TREATMENT EVALUATION.pptBIMALESHYADAV2
This document discusses nephrotic syndrome and proteinuria. It begins by defining nephrotic syndrome as heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. It then discusses the pathophysiology of edema in nephrotic syndrome. The document covers incidence, etiology, clinical manifestations, diagnosis, and treatment of nephrotic syndrome including indications for hospitalization, diuretic therapy, and renal biopsy. It also discusses complications, prognosis, and treatment approaches for first episodes and relapses.
This document provides an overview of nephrotic syndrome, including its pathogenesis, clinical manifestations, investigations, and management. Some key points:
- Nephrotic syndrome is characterized by massive proteinuria, hypoalbuminemia, edema, and hyperlipidemia. It is mostly seen in children aged 2-6 years.
- The podocyte plays a crucial role in the glomerular filtration barrier and podocyte injury can lead to nephrotic syndrome.
- Clinical consequences include edema, hyperlipidemia, increased infection risk, and hypercoagulability.
- Corticosteroids are the main treatment for minimal change nephrotic syndrome, with relapses requiring high-
Childhood nephrotic syndrome—current and future therapiesnephropdt
This document summarizes current and future therapies for childhood nephrotic syndrome. It discusses the various causes and definitions of nephrotic syndrome. Currently available treatments include corticosteroids, cytotoxic drugs, calcineurin inhibitors, mycophenolate mofetil, plasmapheresis, and rituximab. Newer approaches discussed include galactose, adalimumab, thiazolidinediones, and targeting pathways such as Notch signaling, IL-13, unfolded protein response, and redox homeostasis. Future therapies may involve modulating these pathways through inhibitors or stabilizing protein folding.
Nephrotic syndrome, Characterized by heavy proteinuria>3.5g/m/day in adults,>...FarsanaM
Nephrotic syndrome, in paediatric patients(children), mainly Minimal change nephrotic syndrome (MCNS),Characterized by heavy proteinuria>3.5g/m/day in adults,>1g/m/day in children, hypoalbuminemia <2.5g/dL, oedema, hyperlipidemia 200mg/dL, Pathogenesis of MMCNS injury to the glomerular visceral epithelial cell( Podocyte) foot processes
This document provides an overview of nephrotic syndrome in children. It defines nephrotic syndrome as a glomerular disease characterized by heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. The document discusses the epidemiology, etiology, pathophysiology, clinical features, investigations, treatment, complications, and prognosis of nephrotic syndrome. It notes that the majority of nephrotic syndrome cases in children are primary or idiopathic in nature and often steroid-responsive. The long-form document provides detailed information on different types of nephrotic syndrome and their clinical management.
A 6-year-old male child was admitted to the pediatric ward with complaints of cough for 2 days, facial swelling for 10 days, and abdominal distension for 10 days. Laboratory tests found proteinuria, hyperlipidemia, and decreased urine output. The child was diagnosed with nephrotic syndrome and treated with antibiotics, a salt-restricted diet, diuretics, and steroids. Nephrotic syndrome is characterized by proteinuria, hyperlipidemia, edema, and hypoalbuminemia. The causes include minimal change disease, focal segmental glomerulosclerosis, and diabetic nephropathy. Treatment focuses on managing edema, replacing protein loss, lowering lipids, and in some cases using st
This document discusses nephrotic syndrome, which is characterized by proteinuria, hypoalbuminemia, and edema. It defines nephrotic syndrome and outlines its causes, which include genetic, secondary, and idiopathic factors. The pathophysiology involves disturbances in the immune system and mutations affecting glomerular filtration. Clinical features and laboratory findings are provided for different types. Management involves treating symptoms, infections, and relapses with corticosteroids and immunosuppressants. Complications include edema, infections, thrombosis, and renal failure. Prognosis depends on response to steroids, with minimal change disease having a good prognosis and focal segmental glomerulosclerosis having poorer outcomes.
17 february lupus nephritis prof ashraf foudaFarragBahbah
This document discusses key points about lupus nephritis. It notes that 35% of adults with SLE have clinical evidence of nephritis at diagnosis, and 50-60% develop nephritis within 10 years. Lupus nephritis reduces survival at 10 years to 88% compared to 92% for SLE alone. Renal biopsy is recommended for confirmed proteinuria over 0.5 g/24h or active urine sediment. Repeat biopsy may be considered for worsening renal function or unexplained changes. Treatment typically involves steroids like prednisone combined with immunosuppressants like MMF or cyclophosphamide. While initial response rates are similar, steroids alone is associated with more relapses. Long term
Nephrotic syndrome is characterized by nephrotic range proteinuria, hypoalbuminemia, hyperlipidemia, and edema. It is mostly caused by primary glomerular abnormalities. The majority of cases are idiopathic minimal change disease. Steroids are the first line treatment and frequent relapses are managed with immunosuppressants. Complications include infections, thromboembolism, and steroid toxicity. Prognosis is generally good but depends on underlying pathology and response to treatment. Congenital nephrotic syndrome presents in infants and has a heterogeneous genetic cause.
Nephrotic syndrome is characterized by heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. The most common cause is minimal change disease. Treatment involves corticosteroids as initial therapy, with cyclophosphamide or other immunosuppressants used for frequent relapses or steroid resistance. Supportive care focuses on managing edema, diet, and preventing infections, which are a major complication. Kidney biopsy may be needed to identify underlying renal pathology or guide treatment decisions.
This document discusses a case scenario involving a 50-year-old male patient with diabetes and chronic kidney disease (CKD) who is admitted with urosepsis and acute kidney injury (AKI). Over the course of his hospital stay, the patient's kidney function declines and he requires renal replacement therapy. The document poses questions at various points in the case and provides answers regarding evaluating and managing the patient's AKI. It emphasizes identifying reversible causes, preventing progression through fluid management, and considering RRT for severe AKI.
Presented at Belfast City Hospital Physician's Meeting.
Topic - A case of Focal Segmental Glomerulosclerosis with all the complications of nephrotic syndrome and transplant recurrence of FSGS.
4-1. Steroid-sensitive nephrotic syndrome. Francesco Emma (eng)KidneyOrgRu
This document provides definitions and guidelines for treating steroid-sensitive nephrotic syndrome (SSNS) in children. It discusses that SSNS responds well to prednisone treatment within 4 weeks. The optimal duration of prednisone treatment is debated, with some evidence that longer treatment (3-6 months) reduces relapse risk compared to shorter courses, though it increases steroid toxicity risks. For children who frequently relapse or are steroid dependent, calcineurin inhibitors, mycophenolate mofetil, levamisole, and rituximab may be effective steroid-sparing agents, with varying risks and levels of evidence supporting each option. The document outlines guidelines but notes treatment must be tailored to each individual child
Nephrotic syndrome is a kidney disorder characterized by massive edema, low albumin levels, high cholesterol, and heavy protein in urine. It most commonly affects children ages 2-6 years old and is more prevalent in boys. The primary type is idiopathic and thought to be autoimmune. It causes alterations to the glomerular membrane, increasing protein loss in urine. Symptoms include edema, ascites, weight gain, and fatigue. Diagnosis involves testing urine protein and albumin levels. Treatment focuses on steroids, diuretics, diet, and managing complications like infection.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
2. MCQ
A 10-year-old female student with NS (10 g/day)
She is started on oral prednisone with good response (proteinuria
250 mg/day) in 9 weeks.
Prednisone is slowly tapered to 5 mg every other day.
After 2 years of remission, she presents to the clinic with
peripheral edema, and urinary protein excretion increased to 6.5
g/day. Her renal function is normal.
Which one of the following urinary findings is SUGGESTIVE of
relapse of her nephrotic syndrome?
A. Urinary albumin: protein ratio
B. Urinary neutrophil gelatinase-associated lipocalin (NGAL)
C. Monocyte chemo attractant protein-1 (MCP-1)
D. Urinary CTLA-4
E. Urinary CD80
3. LEARNING OBJECTIVES
VARIOUS DEFINITIONS RELEVANT TO NS
LARGEST STUDY ON NS IN CHILDREN ISKDC
SECONDARY CAUSES & CLINICAL FEATURES OF MCD
HYPOTHETICAL ASPECTS OF PATHOGENESIS OF MCD
MANAGEMENT OF MCD IN CHILDREN IN LIGHT OF KDIGO GUIDELINES
4. Major cause of idiopathic Nephrotic syndrome
• Characterized by intense proteinuria leading to edema and
intravascular volume depletion
• In children >1 year of age >>> MCD accounts for 80% of cases
• In Adults >>> 10%-20% of cases of NS
• Around 3rd Decade and later on, membranous nephropathy,
become more frequent
5.
6.
7. 10–50 cases per 1,00,000 children
More common in Asia
Epidemiology
10–50 cases per 1,00,000 children
It is more common in Asians and Native Americans
Much rarer in African Americans, in whom NS is much more
likely to be caused by FSGS.
Male predominance (approximately 2:1)
MCD is much less frequent in adults But ( M:F 1:1)
Seasonal influence incidence Higher during winter
8. INTERNATIONAL STUDY OF KIDNEY DISEASE IN CHILDREN (ISKDC)
The largest and Very OLD study carried out in children with Nephrotic syndrome
Between January, 1967, and April, 1976,
521 CHILDREN WITH THE NEPHROTIC SYNDROME WERE ALLOCATED
(age range 12 weeks to 16 years of age)
All patients satisfied the following criteria:
(1) Heavy proteinuria > 40 mg/ hour/m 2, determined quantitatively on an
overnight collection;
(2) Hypoalbuminemia < 2.5 gm/dl;
(3) Age > 12 weeks and < 16 years;
(4) No prior treatment with steroids or other cytotoxic immunosuppressive
agents; and
(5) No evidence of underlying systemic disease or exposure to agents known to
be associated with the Nephrotic syndrome.
ALL CHILDREN WERE BIOPSIED
9. Of the 521 Children in (ISKDC) study idiopathic nephrotic syndrome
between 1967 and 1974, the following findings were made based upon
kidney biopsy
● MCD − 77 percent MOST COMMON
● MPGN − 8 percent
● FSGS − 7 percent
● Proliferative glomerulonephritis − 2 percent
● Mesangial proliferation − 2 percent
● Focal and global glomerulosclerosis − 2 percent
● Membranous glomerulonephropathy − 2 percent
10. Age (Yrs) Total N Pts with MCD Pts with other lesions
n (n/N)100 n (n/N)100
All Ages 471 363 77 108 23
<6 ===== 332 289 87 43 13
>6 ===== 139 74 53 65 47
RESPONDERS 92% WERE MCD
All Ages 368 338 92 30 8
<6 ===== 284 266 94 18 6
>6 ===== 84 72 85 12 15
NON RESPONDERS 75 % WERE NON-MCD
All Ages 103 25 25 78 75
<6 ===== 48 23 48 25 52
>6 ===== 55 2 4 53 96
MCD and other histopathological categories according to age and
response to prednisone AT EIGHT WEEKS (50 RAN AWAY)
11. ● Age younger than ten years of age
●Absence of hypertension
●Absence of hematuria
●Normal complement levels
●Normal kidney function
One exception to the age criterion is onset of Nephrotic
syndrome in the first year of life, particularly the first three
months of life,
more likely to be due to a gene mutation and to be
resistant to glucocorticoids.
After ISKDC Study
An initial trial of steroid therapy is generally administered to
children who are likely to have MCD based upon clinical
diagnosis, THEREBY AVOIDING KIDNEY BIOPSY.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21. I N C H I L D R E N with NS
it is clinically important to differentiate as early as
possible in the course of the disease between patients
with MCD and those with other glomerular lesions.
Decisions concerning
• The need for renal biopsy,
• Optimal initial treatment, and
• Predictions concerning prognosis depend upon this
differentiation.
22. PARENTS ARE WORRIED AND CONCERNED
PARENTS OF CHILDREN WITH MCNS CAN BE TOLD
That the prognosis for complete RECOVERY IS EXCELLENT,
That a renal biopsy probably will NOT BE NECESSARY, and
That Prednisone can in most instances SUPPRESS THE SYMPTOMS
IN CONTRAST
PARENTS OF CHILDREN WITH OTHER LESIONS MUST KNOW
That the disease may progress to ESRD,
That ONE OR MORE renal biopsies may be required, and
That, at present, there is NO KNOWN DEFINITIVE treatment?.
25. DEFINITIONS..
Nephrotic Syndrome
Edema
Massive proteinuria (>40 mg/m2 per h in children, >3.5 g/d in adults)
uPCR ≥2000 mg/g
Hypoalbuminemia (<2.5 g/dl)
Remission
Resolution of edema WITH Marked reduction in proteinuria
Normalization of serum albumin (≥3.5 g/dl)
COMPLETE REMISSION (<4 mg/m2 per h or negative dipstick in children, <0.3
g/d in adults) uPCR <200 mg/g
PARTIAL REMISSION Reduction by ≥50% ; uPCR between 200 and
2000mg/g and serum albumin ≥2.5 g/dl in children, 0.21 g/day and 3.4 g/day and
decreased by ≥50% in adults)
26. Relapse
Recurrence of massive proteinuria uPCR ≥2000 mg/g in children, >3.5 g/d in adults)
Positive urine dipstick (≥3+ for 3 d or positive for 7 d, usually applicable to children)
±Edema
Steroid-Sensitive Nephrotic Syndrome
Initial responder Attainment of complete remission within initial 4 wk of
corticosteroid therapy BEST PROGNOSIS
Response to PDN 60 mg/m2 per d within 4–6 wk ±MPD boluses in children
Response to PDN 1 mg/kg per d or 2 mg/kg every other d, within 16 wk in adults
27. Most patients who are to respond to steroids do so within 4 weeks.
50% of children achieve remission within 8 days of RECOMMENDED
steroid treatment
90% of Children Achieve Remission following Steroids.
However Relapses tend to be more rapid in children
In both populations, MCD has a high tendency to relapse
In contrast, in adults the median time to remission exceeds 2 months
28. NONRELAPSING NS VERY GOOD PROGNOSIS
No relapses for >2 yr. after the end of therapy for the first episode of
Nephrotic syndrome (applicable to children, not yet defined in
adults)
Infrequently Relapsing Nephrotic Syndrome
<2 relapses per 6 months (or <4 relapses per 12 months)
Frequently Relapsing Nephrotic Syndrome
≥2 relapses per 6 months (or ≥4 relapses per 12 months)
29. STEROID-DEPENDENT NEPHROTIC SYNDROME
Two consecutive relapses DURING STEROID THERAPY, or
WITHIN 14 DAYS of discontinuation of steroid therapy
STEROID-RESISTANT NEPHROTIC SYNDROME
In children No response to PDN 60 mg/m2 per d within 08 wk.
In adults No response to PDN 1 mg/kg/d or 2 mg/kg EOD within 16wk.
30. WHEN TO BIOPSY???
In adults EARLY KIDNEY BIOPSY is crucial
The indications for renal biopsy in CHILDREN are
Onset, age <1 or >12 years
Gross hematuria
Low serum C3
Marked hypertension
Renal failure without severe hypovolemic
Positive history for secondary cause
Steroid resistance or therapy with Calcineurin inhibitors
31. • By LM, NOTHING IN LIGHT MICROSCOPY (NIL DISEASE)
• Sometimes- mild focal meningeal prominence not
exceeding three or four cells per segment are seen.
HISTOPATHOLOGY
32. Immunofluorescence is USUALLY NEGATIVE.
• However, low-intensity mesangial IgM (sometimes
accompanied by C3 or C1q) staining can be found.
• MCD is occasionally accompanied by glomerular IgA
deposits-IgA nephropathy with MCD 5% Of IgA
• Focal segmental distribution of IgM and C3
staining should strongly suggest FSGS
IMMUNOFLUORESCENCE
37. o Edema- Periorbital, scrotum or labia and lower extremities
o Edema increases RAPIDLY and becomes detectable when
fluid retention exceeds 3 to 5 percent of body weight.
o Severe infections such as Sepsis, Pneumonia, and Peritonitis
o Bowel edema may manifest as Abd Pain & diarrhea
o Intravascular volume depletion and oliguria - AKI, which is
more frequently seen in adults.
o Rarely, AKI with gross hematuria followed by anuria -
secondary to bilateral renal vein thrombosis.
CLINICAL MANIFESTATIONS
38. IN CONTRAST TO OTHER GLOMERULAR DISEASES
MCD is associated with NORMAL BLOOD PRESSURE.
Some patients may develop transient renin mediated hypertension during
relapse from hypovolemia and renal hypo perfusion.
Paradoxically, blood pressure will normalize after albumin infusion as the intravascular
compartment is restored.
Hypertension also can be iatrogenic, secondary to use of STEROIDS, AND CNIS.
Sustained hypertension QUESTIONS YOUR DIAGNOSIS .
39. LAB VALUES
• Urinalysis, with urinary dipstick showing 3+/4+ proteinuria
• Nephrotic-range proteinuria > 50 mg/kg/day or
> 40 mg/m2/hour
• Urine PCR >200 mg/mmol in children and
• Urine proteins >3.5 g/d in adults
• Serum albumin<2 g/dl
• Urinalysis relatively inactive urine sediment (ie, oval fat bodies
and hyaline casts, but few red cells and no red cell or other
cellular casts).
• Lipid Profile
• IgG is markedly decreased
40. NONIMMUNE GENERAL MEASURES These Include
Prevention of infection –
Pneumococcal, INFLUENZA and varicella vaccines.
AVOID LIVE VACCINATIONS DURING RELAPSE
Identification and treatment of suspected infections (pneumonia, cellulitis,
sepsis, peritonitis) as these patients are immunosuppressed.
Management of edema with avoidance of excessive fluid intake, moderate
restriction of dietary salt, elevation of extremities, and judicious use of
diuretics.
IV ALBUMIN HAS TWO ROLES
1) Prevention of venous thromboembolism and
2) Avoidance of intravascular hypovolemia
Maintenance of adequate protein intake (130 to 140 percent of the
recommended daily allowance)
MANAGEMENT
41. WHAT KDIGO GUIDELINES RECOMMEND
NOMENCLATURE AND DESCRIPTION FOR RATING GUIDELINE RECOMMENDATIONS
Within each recommendation,
STRENGTH OF RECOMMENDATION is indicated as Level 1 or Level 2,
QUALITY OF THE SUPPORTING EVIDENCE is shown as A, B, C, or D.
42. Grade
Implications
Clinicians Patients
Level 1
“We recommend”
MOST CLINICIANS in your
situation would want the
recommended course of action,
and only a small proportion
would not.
Most patients should
receive the
recommended course of
action.
Level 2
“We suggest”
MAJORITY OF PEOPLE in your
situation would want the
recommended course of action,
but many would not.
Different choices will be
appropriate for different
patients. Each patient needs help
to arrive at a management
decision consistent with her or
his values and preferences.
43. Grade Quality of evidence Meaning
A High We are confident that the true effect lies close to
the estimate of the effect.
B Moderate The true effect is likely to be close to the estimate
of the effect.
C Low The true effect may be substantially different from
the estimate of the effect.
D Very low The estimate of effect is very uncertain, and often
will be far from the truth.
44. 3.1.1: We recommend that corticosteroid therapy (prednisone or
prednisolone)* be given for at least 12 weeks. (1B) <=
3.1.1.1: We recommend that oral prednisone be administered as a single
daily dose (1B) <= starting at 60 mg/m2 /d or 2 mg/kg/d to a maximum
60 mg/d. (1D)
3.1.1.2: We recommend that daily oral prednisone be given for 4–6 weeks
(1C) followed by alternate-day medication as a single daily dose starting at 40
mg/m2 or 1.5 mg/kg (maximum 40 mg on alternate days) (1D) and continued
for 2–5 months with tapering of the dose. (1B) <=
3.1: Treatment of CHILDREN INITIAL EPISODE
45. 3.2: Treatment of Infrequent Relapsing SSNS
USUALLY SHORT COURSE OF STEROIDS WILL SUFFICE
3.2.1: Corticosteroid therapy for children with INFREQUENT RELAPSES :
3.2.1.1:
We suggest that infrequent relapses of SSNS in children be treated with a
single-daily dose of prednisone 60 mg/m2 or 2 mg/kg (maximum of 60 mg/d)
until the child has been in complete remission for at least 3 days. (2D) <==
3.2.1.2:
We suggest that, after achieving complete remission, children be given
prednisone as a single dose on alternate days (40 mg/m2 per dose or 1.5
mg/kg per dose: maximum 40 mg on alternate days) for at least 4 weeks.
(2C)
46. 3.2.2: Treatment of CHILDREN FR and SD SSNS
BE AWARE OF ADVERSE AFFECTS (LONGER COURSE IS REQUIRED)
3.2.2.1: We suggest that relapses in children with FR or SD SSNS be treated
with daily prednisone until the child has been in remission for at least 3 days, followed
by alternate-day prednisone for at least 3 months. (2C)
3.2.2.2: We suggest that prednisone be given on alternate days in the lowest
dose to maintain remission without major adverse effects in children with FR and SD
SSNS. (2D)
3.2.2.3: We suggest that daily prednisone at the lowest dose be given to
maintain remission without major adverse effects in children with SD SSNS where
alternate-day prednisone therapy is not effective(2D)
3.2.2.4: We suggest that daily prednisone be given during episodes of upper
respiratory tract and other infections to reduce the risk for relapse in children with FR
and SD SSNS already on alternate-day prednisone. (2C)
47. 3.3: Treatment of CHILDREN FR and SD SSNS
TREATMENT WITH CORTICOSTEROID-SPARING AGENTS
3.3.1: We recommend that corticosteroid-sparing agents be prescribed for children with
FR SSNS and SD SSNS, who develop steroid-related adverse effects. (1B) <=
3.3.2: We recommend that alkylating agents, cyclophosphamide or chlorambucil, be
given as corticosteroid-sparing agents for FR SSNS. (1B) <=
We Suggest that alkylating agents, cyclophosphamide or chlorambucil, be given as
corticosteroid-sparing agents for SD SSNS. (2C)
3.3.2.1: We suggest that cyclophosphamide (2 mg/kg/d) be given for 8–12 weeks
(maximum cumulative dose 168 mg/kg). (2C)
3.3.2.2: We suggest that cyclophosphamide not be started until the child has achieved
remission with corticosteroids. (2D)
3.3.2.3: We suggest that chlorambucil (0.1–0.2 mg/kg/d) may be given for 8 weeks
(maximum cumulative dose 11.2 mg/kg) as an alternative to cyclophosphamide. (2C)
3.3.2.4: We suggest that Second Course Of Alkylating Agents NOT Be Given.
(2D)
48. 3.3.3: We recommend that levamisole be given as a corticosteroid-
sparing agent. (1B) <=
3.3.3.1: We suggest that levamisole be given at a dose of 2.5 mg/kg on alternate
days (2B) for at least 12 months (2C) as most children will relapse when
levamisole is stopped.
3.3: Treatment of CHILDREN (FR) and SD SSNS
TREATMENT WITH CORTICOSTEROID-SPARING AGENTS
49. 3.3.4: We recommend that the Calcineurin Inhibitors cyclosporine or
tacrolimus be given as corticosteroid-sparing agents. (1C)
3.3.4.1: We suggest that cyclosporine be administered at a dose of 4–5 mg/kg/d
(starting dose) in two divided doses. (2C)
3.3.4.2: We suggest that tacrolimus 0.1 mg/kg/d (starting dose) given in two divided
doses be used instead of cyclosporine when the cosmetic side-effects of cyclosporine
are unacceptable. (2D)
3.3.4.3: Monitor CNI levels during therapy to limit toxicity. (Not Graded)
3.3.4.4: We suggest that CNIS BE GIVEN FOR AT LEAST 12 MONTHS, as most children
will relapse when CNIs are stopped. (2C)
50. 3.3.5: We suggest that MMF be given as a corticosteroid-sparing
agent. (2C)
3.3.5.1: We suggest that MMF (starting dose 1200 mg/m2 /d) be given in two
divided doses for at least 12 months, as most children will relapse when MMF is
stopped. (2C)
3.3.6: We suggest that rituximabbe considered only in children with SD SSNS
who have continuing frequent relapses despite optimal combinations of prednisone
and corticosteroid-sparing agents, and/or who have serious adverse effects of
therapy. (2C)
3.3.8: We recommend that azathioprine not be used as a
corticosteroid-sparing agent in FR and SD SSNS. (1B)
51. SUMMARY OF (1B) <==> RECOMMENDATIONS
3.1.1: We recommend that corticosteroid therapy (prednisone or
prednisolone)* be given for at least 12 weeks. (1B) <=
3.1.1.1: We recommend that oral prednisone be administered as a single
daily dose (1B) <=
3.1.1.2: We recommend that daily oral prednisone be continued for 2–5
months with tapering of the dose. (1B) <=
3.3.1: We recommend that corticosteroid-sparing agents be prescribed for
children with FR SSNS and SD SSNS, who develop steroid-related adverse effects.
(1B) <=
3.3.2: We recommend that alkylating agents, cyclophosphamide or
chlorambucil, be given as corticosteroid-sparing agents for FR SSNS. (1B) <=
3.3.3: We recommend that levamisole be given as a corticosteroid-sparing
agent. (1B) <=
52. 3.4: Indication for kidney biopsy
3.4.1: Indications for kidney biopsy in children with SSNS are (Not Graded):
Late failure to respond following initial response to corticosteroids;
A high index of suspicion for a different underlying pathology;
Decreasing kidney function in children receiving CNIs.
53. 3.5: Immunizations in children with SSNS
3.5.1: To reduce the risk of serious infections in children with SSNS (Not Graded):
Give pneumococcal vaccination to the children.
Give influenza vaccination annually to the children and their household contacts.
Defer vaccination with live vaccines until prednisone dose is below either 1 mg/kg
daily (o20 mg/d) or 2 mg/kg on alternate days (o40 mg on alternate days).
Live vaccines are contraindicated in children receiving corticosteroid-sparing
immunosuppressive agents. K
Immunize healthy household contacts with live vaccines to minimize the risk of
transfer of infection to the immunosuppressed child but avoid direct exposure of
the child to gastrointestinal, urinary, or respiratory secretions of vaccinated
contacts for 3–6 weeks after vaccination.
Following close contact with Varicella infection, give nonimmune children on
immunosuppressive agents varicella zoster immune globulin, if available.
54. TREATMENT IN CHILDREN STEROID-RESISTANT NS
4.1.1: We suggest a minimum of 8 weeks treatment with corticosteroids to define steroid
resistance. (2D)
4.1.2: The following are required to evaluate the child with SRNS (Not Graded):
a diagnostic kidney biopsy;
evaluation of kidney function by GFR or eGFR;
quantitation of urine protein excretion.
4.2: Treatment recommendations for SRNS
o 4.2.1: We recommend using a calcineurin inhibitor (CNI) as initial therapy for
children with SRNS. (1B) <==
o 4.2.1.1: We suggest that CNI therapy be continued for a minimum of 6 months and
then stopped if a partial or complete remission of proteinuria is not achieved. (2C)
o 4.2.1.2: We suggest CNIs be continued for a minimum of 12 months when at least
a partial remission is achieved by 6 months. (2C)
o 4.2.1.3: We suggest that low-dose corticosteroid therapy be combined with CNI
therapy. (2D)
55. 4.2.2: We recommend treatment with ACE-I or ARBs for children with SRNS. (1B)
4.2.3: In children who fail to achieve remission with CNI therapy:
4.2.3.1: We suggest that mycophenolate mofetil (2D), high-dose corticosteroids
(2D), or a combination of these agents (2D) be considered in children who fail to
achieve complete or partial remission with CNIs and corticosteroids.
4.2.3.2: We suggest that cyclophosphamide not be given to children with SRNS. (2B)
4.2.4: In patients with a relapse of nephrotic syndrome after complete remission,
we suggest that therapy be restarted using any one of the following options: (2C)
Oral corticosteroids (2D);
Return to previous successful immunosuppressive agent (2D);
An alternative immunosuppressive agent to minimize potential cumulative
toxicity (2D).
56. • After remission of the first episode of nephrosis, about
30% NEVER RELAPSE for 18–24 months,
20%–30% progress to infrequent relapses
The remaining 40%–50%, more frequently children <5
years of age, will have a frequently relapsing or steroid-
dependent course
• Initially steroid-sensitive disease will develop secondary
steroid resistance. • This clinical feature is highly predictive
of post-transplant recurrence
In Children,
In adults, relapses are frequent, occurs in about 56%–76%.
Overall Outcome
57. ANSWER
E. Urinary CD80
Urinary CD80 levels are increased during
relapse and normalizes during remission in
children with minimal change disease. Garin
et al.
Unlike CD80, the urinary levels of soluble CTLA-4
are not elevated during relapse of minimal change
disease. However, the ratio of CD80/CTLA-4 is
elevated. Thus, option D is incorrect.